Dwarfism: Clinical Trials

5 trials for Dwarfism, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 enrolling by invitation. 5 Phase 2, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 25Enrolling by invitation 5
Phase 32Enrolling by invitation 2

Follow Dwarfism: new trials by email Literature Review of Dwarfism trials Research Report on Dwarfism

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia
Infigratinib - Hypochondroplasia
Phase 2Enrolling by invitationQED Therapeutics, a BridgeBio company1352026-04-232026-08-26
An Interventional Study of Infigratinib in Children With Hypochondroplasia
infigratinib 0.128 mg/kg/day, infigratinib 0.25 mg/kg/day - Hypochondroplasia
Phase 2 / Phase 3Enrolling by invitationQED Therapeutics, a BridgeBio company242025-04-222026-07-16
A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial (OraGrowtH211)
LUM-201 - Growth Hormone Deficiency
Phase 2Enrolling by invitationLumos Pharma602023-08-012024-02-15
A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia
TransCon CNP - Achondroplasia
Phase 2 / Phase 3Enrolling by invitationAscendis Pharma Growth Disorders A/S1402023-06-212026-08-17
Extension Study of Infigratinib in Children With Achondroplasia (ACH)
Infigratinib - Achondroplasia
Phase 2Enrolling by invitationQED Therapeutics, a BridgeBio company3252021-12-062026-10-26

Narrower conditions

Bone Diseases (3)  ·  Genetic Diseases, Inborn (3)  ·  Mucopolysaccharidosis IV (3)  ·  Musculoskeletal Diseases (3)  ·  Osteochondrodysplasias (3)  ·  Achondroplasia (2)  ·  Hypochondroplasia (2)  ·  Dwarfism, Pituitary (1)

Broader conditions

Bone Diseases, Developmental (5)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4)  ·  Endocrine System Diseases (4)  ·  Carbohydrate Metabolism, Inborn Errors (3)  ·  Connective Tissue Diseases (3)  ·  Lysosomal Storage Diseases (3)  ·  Metabolic Diseases (3)  ·  Metabolism, Inborn Errors (3)  ·  Mucinoses (3)  ·  Mucopolysaccharidoses (3)  ·  Nutritional and Metabolic Diseases (3)  ·  Skin and Connective Tissue Diseases (3)  ·  Bone Diseases (2)  ·  Musculoskeletal Diseases (2)

Interventions

infigratinib (3)

Sponsors

QED Therapeutics, a BridgeBio company (3)  ·  Ascendis Pharma Growth Disorders A/S (1)  ·  Lumos Pharma (1)

Countries

Australia (5)  ·  United States (5)  ·  Canada (4)  ·  France (4)  ·  Spain (4)  ·  United Kingdom (4)  ·  Norway (3)  ·  Portugal (3)  ·  Singapore (3)  ·  Sweden (2)  ·  Argentina (1)  ·  Austria (1)  ·  Denmark (1)  ·  Germany (1)  ·  Ireland (1)